Literature DB >> 17644455

Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.

Francisca H C Zanin1, Eduardo A F Coelho, Carlos A P Tavares, Eduardo A Marques-da-Silva, Miriam Maria Silva Costa, Simone A Rezende, Ricardo T Gazzinelli, Ana Paula Fernandes.   

Abstract

Several antigens have been tested as vaccine candidates against Leishmania infections but controversial results have been reported when different antigens are co-administered in combined vaccination protocols. Immunization with A2 or nucleoside hydrolase (NH) antigens was previously shown to induce Th1 immune responses and protection in BALB/c mice against Leishmania donovani and L. amazonensis (A2) or L. donovani and L. mexicana (NH) infections. In this work, we investigated the protective efficacy of A2 and NH DNA vaccines, in BALB/c mice, against L. amazonensis or L. chagasi challenge infection. Immunization with either A2 (A2-pCDNA3) or NH (NH-VR1012) DNA induced an elevated IFN-gamma production before infection; however, only A2 DNA immunized mice were protected against both Leishmania species and displayed a sustained IFN-gamma production and very low IL-4 and IL-10 levels, after challenge. Mice immunized with NH/A2 DNA produced higher levels of IFN-gamma in response to both specific recombinant proteins (rNH or rA2), but displayed higher IL-4 and IL-10 levels and increased edema and parasite loads after L. amazonensis infection, as compared to A2 DNA immunized animals. These data extend the characterization of the immune responses induced by NH and A2 antigens as potential candidates to compose a defined vaccine and indicate that a highly polarized type 1 immune response is required for improvement of protective levels of combined vaccines against both L. amazonensis and L. chagasi infections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17644455     DOI: 10.1016/j.micinf.2007.05.012

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  19 in total

Review 1.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

2.  Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.

Authors:  Beatriz Coutinho De Oliveira; Malcolm S Duthie; Valéria Rêgo Alves Pereira
Journal:  Hum Vaccin Immunother       Date:  2019-11-11       Impact factor: 3.452

3.  Evaluation of parasitological and immunological parameters of Leishmania chagasi infection in BALB/c mice using different doses and routes of inoculation of parasites.

Authors:  Dulcilene M Oliveira; Mariana Amália F Costa; Miguel A Chavez-Fumagalli; Diogo G Valadares; Mariana C Duarte; Lourena E Costa; Vivian T Martins; Rosângela F Gomes; Maria N Melo; Manuel Soto; Carlos Alberto P Tavares; Eduardo Antonio F Coelho
Journal:  Parasitol Res       Date:  2011-09-14       Impact factor: 2.289

4.  A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis.

Authors:  Vivian T Martins; Mariana C Duarte; Miguel A Chávez-Fumagalli; Daniel Menezes-Souza; Cecília S P Coelho; Danielle F de Magalhães-Soares; Ana Paula Fernandes; Manuel Soto; Carlos A P Tavares; Eduardo A F Coelho
Journal:  Parasit Vectors       Date:  2015-07-11       Impact factor: 3.876

5.  Mitigating an undesirable immune response of inherent susceptibility to cutaneous leishmaniosis in a mouse model: the role of the pathoantigenic HISA70 DNA vaccine.

Authors:  Gustavo Domínguez-Bernal; Pilar Horcajo; José A Orden; Ricardo De La Fuente; Aldara Herrero-Gil; Lara Ordóñez-Gutiérrez; Javier Carrión
Journal:  Vet Res       Date:  2012-08-09       Impact factor: 3.683

6.  Development of Vaccines against Visceral Leishmaniasis.

Authors:  Krystal J Evans; Lukasz Kedzierski
Journal:  J Trop Med       Date:  2011-09-05

7.  Vaccine effectiveness and use of collar impregnated with insecticide for reducing incidence of Leishmania infection in dogs in an endemic region for visceral leishmaniasis, in Brazil.

Authors:  E G Lopes; A P Sevá; F Ferreira; C M Nunes; L B Keid; R M Hiramoto; H L Ferreira; T M F S Oliveira; F G Ovallos; E A B Galati; T J Villegas; D V Bortoletto; S Y O B Valadas; R M Soares
Journal:  Epidemiol Infect       Date:  2018-01-18       Impact factor: 4.434

8.  HisAK70: progress towards a vaccine against different forms of leishmaniosis.

Authors:  Gustavo Domínguez-Bernal; Pilar Horcajo; José A Orden; José A Ruiz-Santa-Quiteria; Ricardo De La Fuente; Lara Ordóñez-Gutiérrez; Abel Martínez-Rodrigo; Alicia Mas; Javier Carrión
Journal:  Parasit Vectors       Date:  2015-12-09       Impact factor: 3.876

9.  Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis.

Authors:  Vivian T Martins; Miguel A Chávez-Fumagalli; Lourena E Costa; Adriana M C Canavaci; Adriana M C C Martins; Paula S Lage; Daniela P Lage; Mariana C Duarte; Diogo G Valadares; Rubens D M Magalhães; Tatiana G Ribeiro; Ronaldo A P Nagem; Wanderson D Darocha; Wiliam C B Régis; Manuel Soto; Eduardo A F Coelho; Ana Paula Fernandes; Carlos A P Tavares
Journal:  PLoS Negl Trop Dis       Date:  2013-03-28

10.  Antigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral Leishmaniasis.

Authors:  Vivian Tamietti Martins; Miguel Angel Chávez-Fumagalli; Daniela Pagliara Lage; Mariana Costa Duarte; Esther Garde; Lourena Emanuele Costa; Viviane Grazielle da Silva; Viviane Gomes da Silva; Jamil Silvano Oliveira; Danielle Ferreira de Magalhães-Soares; Santuza Maria Ribeiro Teixeira; Ana Paula Fernandes; Manuel Soto; Carlos Alberto Pereira Tavares; Eduardo Antonio Ferraz Coelho
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.